MAPK1 and melanoma: PLX4032, (vemurafenib) an ATP-competitive RAF inhibitor, inhibits ERK signaling and cell proliferation in BRAFV600E melanomas, but enhances the signaling in BRAFWT cells with mutated NRAS [21, 22].